RU2510503C2 - Модулирование хемосенсорных рецепторов и связанных с ними лигандов - Google Patents

Модулирование хемосенсорных рецепторов и связанных с ними лигандов Download PDF

Info

Publication number
RU2510503C2
RU2510503C2 RU2009148316/15A RU2009148316A RU2510503C2 RU 2510503 C2 RU2510503 C2 RU 2510503C2 RU 2009148316/15 A RU2009148316/15 A RU 2009148316/15A RU 2009148316 A RU2009148316 A RU 2009148316A RU 2510503 C2 RU2510503 C2 RU 2510503C2
Authority
RU
Russia
Prior art keywords
substituted
category
alkyl
composition
heteroalkyl
Prior art date
Application number
RU2009148316/15A
Other languages
English (en)
Other versions
RU2009148316A (ru
Inventor
Кэтрин ТАЧДЖИАН
Доналд С. КАРАНЕВСКИЙ
Сяо-цин ТАН
Сяодун ЛИ
Фын ЧЖАН
Гай СЕРВАНТ
Цин Чэнь
Винсент ДАРМОХИСОДО
Ричард ФАЙН
Джозеф Р. ФОТСИНГ
Джеффри Роберт ХЭММЕЙКЕР
Синьшань КАН
Рашель Д.А. КИММИЧ
Борис КЛЕБАНСКИЙ
Хайтянь ЛЮ
Горан ПЕТРОВИЧ
Маркета РИННОВА
Сара АДАМСКИ-ВЕРНЕР
Джеффри ЯМАМОТО
Хун Чжан
Альберт ЗЛОТНИК
Марк ЗОЛЛЕР
Original Assignee
Синомикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/760,592 external-priority patent/US9603848B2/en
Application filed by Синомикс, Инк. filed Critical Синомикс, Инк.
Publication of RU2009148316A publication Critical patent/RU2009148316A/ru
Application granted granted Critical
Publication of RU2510503C2 publication Critical patent/RU2510503C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/31—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A23L27/34—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/88—Taste or flavour enhancing agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)

Abstract

Группа изобретений относится к соединениям - модификаторам хемосенсорных рецепторов и их лигандов, имеющим структурную формулу (IIIb), их подвидам и конкретным соединениям, съедобным композициям, содержащим модификаторы хемосенсорных рецепторов и их лигандов, имеющие структурную формулу (IIIb), их подвиды и конкретные соединения, а также к способам применения вышеуказанных соединений для улучшения сладкого вкуса съедобных композиций. Соединения данной группы изобретений обеспечивают возможность получения и улучшения сладкого вкуса. 6 н. и 18 з.п. ф-лы, 19 ил., 44 табл., 813 пр.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167
Figure 00000168
Figure 00000169
Figure 00000170
Figure 00000171
Figure 00000172
Figure 00000173
Figure 00000174
Figure 00000175
Figure 00000176
Figure 00000177
Figure 00000178
Figure 00000179
Figure 00000180
Figure 00000181
Figure 00000182
Figure 00000183
Figure 00000184
Figure 00000185
Figure 00000186
Figure 00000187
Figure 00000188
Figure 00000189
Figure 00000190
Figure 00000191
Figure 00000192
Figure 00000193
Figure 00000194
Figure 00000195
Figure 00000196
Figure 00000197
Figure 00000198
Figure 00000199
Figure 00000200
Figure 00000201
Figure 00000202
Figure 00000203
Figure 00000204
Figure 00000205
Figure 00000206
Figure 00000207
Figure 00000208
Figure 00000209
Figure 00000210
Figure 00000211
Figure 00000212
Figure 00000213
Figure 00000214
Figure 00000215
Figure 00000216
Figure 00000217
Figure 00000218
Figure 00000219
Figure 00000220
Figure 00000221
Figure 00000222
Figure 00000223
Figure 00000224
Figure 00000225
Figure 00000226
Figure 00000227
Figure 00000228
Figure 00000229
Figure 00000230
Figure 00000231
Figure 00000232
Figure 00000233
Figure 00000234
Figure 00000235
Figure 00000236
Figure 00000237
Figure 00000238
Figure 00000239
Figure 00000240
Figure 00000241
Figure 00000242
Figure 00000243
Figure 00000244
Figure 00000245
Figure 00000246
Figure 00000247
Figure 00000248
Figure 00000249
Figure 00000250
Figure 00000251
Figure 00000252
Figure 00000253
Figure 00000254
Figure 00000255
Figure 00000256
Figure 00000257
Figure 00000258
Figure 00000259
Figure 00000260
Figure 00000261
Figure 00000262
Figure 00000263
Figure 00000264
Figure 00000265
Figure 00000266
Figure 00000267
Figure 00000268
Figure 00000269
Figure 00000270
Figure 00000271
Figure 00000272
Figure 00000273
Figure 00000274
Figure 00000275
Figure 00000276
Figure 00000277
Figure 00000278
Figure 00000279
Figure 00000280
Figure 00000281
Figure 00000282
Figure 00000283
Figure 00000284
Figure 00000285
Figure 00000286
Figure 00000287
Figure 00000288
Figure 00000289
Figure 00000290
Figure 00000291
Figure 00000292
Figure 00000293
Figure 00000294
Figure 00000295
Figure 00000296
Figure 00000297
Figure 00000298
Figure 00000299
Figure 00000300
Figure 00000301
Figure 00000302
Figure 00000303
Figure 00000304
Figure 00000305
Figure 00000306
Figure 00000307
Figure 00000308
Figure 00000309
Figure 00000310
Figure 00000311
Figure 00000312
Figure 00000313
Figure 00000314
Figure 00000315
Figure 00000316
Figure 00000317
Figure 00000318
Figure 00000319
Figure 00000320
Figure 00000321
Figure 00000322
Figure 00000323
Figure 00000324
Figure 00000325
Figure 00000326
Figure 00000327
Figure 00000328
Figure 00000329
Figure 00000330
Figure 00000331
Figure 00000332
Figure 00000333
Figure 00000334
Figure 00000335
Figure 00000336
Figure 00000337
Figure 00000338
Figure 00000339
Figure 00000340
Figure 00000341
Figure 00000342
Figure 00000343
Figure 00000344
Figure 00000345
Figure 00000346
Figure 00000347
Figure 00000348
Figure 00000349
Figure 00000350
Figure 00000351
Figure 00000352
Figure 00000353
Figure 00000354
Figure 00000355
Figure 00000356
Figure 00000357
Figure 00000358
Figure 00000359
Figure 00000360
Figure 00000361
Figure 00000362
Figure 00000363
Figure 00000364
Figure 00000365
Figure 00000366
Figure 00000367
Figure 00000368
Figure 00000369
Figure 00000370
Figure 00000371
Figure 00000372
Figure 00000373
Figure 00000374
Figure 00000375
Figure 00000376
Figure 00000377
Figure 00000378
Figure 00000379
Figure 00000380
Figure 00000381
Figure 00000382
Figure 00000383
Figure 00000384
Figure 00000385
Figure 00000386
Figure 00000387
Figure 00000388
Figure 00000389
Figure 00000390
Figure 00000391
Figure 00000392
Figure 00000393
Figure 00000394
Figure 00000395
Figure 00000396
Figure 00000397
Figure 00000398
Figure 00000399
Figure 00000400
Figure 00000401
Figure 00000402
Figure 00000403
Figure 00000404
Figure 00000405
Figure 00000406
Figure 00000407
Figure 00000408
Figure 00000409
Figure 00000410
Figure 00000411
Figure 00000412
Figure 00000413
Figure 00000414
Figure 00000415
Figure 00000416
Figure 00000417
Figure 00000418
Figure 00000419
Figure 00000420
Figure 00000421
Figure 00000422
Figure 00000423
Figure 00000424
Figure 00000425
Figure 00000426
Figure 00000427
Figure 00000428
Figure 00000429
Figure 00000430
Figure 00000431
Figure 00000432
Figure 00000433
Figure 00000434
Figure 00000435
Figure 00000436
Figure 00000437
Figure 00000438
Figure 00000439
Figure 00000440
Figure 00000441
Figure 00000442
Figure 00000443
Figure 00000444
Figure 00000445
Figure 00000446
Figure 00000447
Figure 00000448
Figure 00000449
Figure 00000450
Figure 00000451
Figure 00000452
Figure 00000453
Figure 00000454
Figure 00000455
Figure 00000456
Figure 00000457
Figure 00000458
Figure 00000459
Figure 00000460
Figure 00000461
Figure 00000462
Figure 00000463
Figure 00000464
Figure 00000465
Figure 00000466
Figure 00000467
Figure 00000468
Figure 00000469
Figure 00000470
Figure 00000471
Figure 00000472
Figure 00000473
Figure 00000474
Figure 00000475
Figure 00000476
Figure 00000477
Figure 00000478
Figure 00000479
Figure 00000480
Figure 00000481
Figure 00000482
Figure 00000483
Figure 00000484
Figure 00000485
Figure 00000486
Figure 00000487
Figure 00000488
Figure 00000489
Figure 00000490
Figure 00000491
Figure 00000492
Figure 00000493
Figure 00000494
Figure 00000495
Figure 00000496
Figure 00000497
Figure 00000498
Figure 00000499
Figure 00000500
Figure 00000501
Figure 00000502
Figure 00000503
Figure 00000504
Figure 00000505
Figure 00000506
Figure 00000507
Figure 00000508
Figure 00000509
Figure 00000510
Figure 00000511
Figure 00000512
Figure 00000513
Figure 00000514
Figure 00000515
Figure 00000516
Figure 00000517
Figure 00000518
Figure 00000519
Figure 00000520
Figure 00000521
Figure 00000522
Figure 00000523
Figure 00000524
Figure 00000525
Figure 00000526
Figure 00000527
Figure 00000528
Figure 00000529
Figure 00000530
Figure 00000531
Figure 00000532
Figure 00000533
Figure 00000534
Figure 00000535
Figure 00000536
Figure 00000537
Figure 00000538
Figure 00000539
Figure 00000540
Figure 00000541
Figure 00000542
Figure 00000543
Figure 00000544
Figure 00000545
Figure 00000546
Figure 00000547
Figure 00000548
Figure 00000549
Figure 00000550
Figure 00000551
Figure 00000552
Figure 00000553
Figure 00000554
Figure 00000555
Figure 00000556
Figure 00000557
Figure 00000558
Figure 00000559
Figure 00000560
Figure 00000561
Figure 00000562
Figure 00000563
Figure 00000564
Figure 00000565
Figure 00000566

Claims (24)

1. Соединение, имеющее структурную формулу (IIIb):
Figure 00000567

или его таутомер, соль, сольват и/или его сложный эфир, где
A является NH2;
Н является -C(R35)- или -N-;
I является -C(R36)- или -N-;
J является -C(R37)- или -N-;
K является -C(R38)-;
R17 является водородом;
R35 является водородом;
R36 является водородом;
R37 является водородом, фтором, хлором или бромом;
R38 является алкенилом, замещенным алкенилом, алкинилом, замещенным алкинилом, циклоалканилом, замещенным циклоалканилом, циклоалкенилом, замещенным циклоалкенилом, гетероалкилом, замещенным гетероалкилом, циклогетероалкилом, замещенным циклогетероалкилом, -O-алканилом, -O-(замещенным алканилом), -O-гетероалкилом, -O-(замещенным гетероалкилом), -O-алкенилом, -O-(замещенным алкенилом), -NH-алканилом, -NH-(замещенным алканилом), -NH-алкенилом, -NH-(замещенным алкенилом), -S-алканилом, -S-(замещенным алканилом), -S-алкенилом или -S-(замещенным алкенилом).
2. Соединение по п.1,
где Н является -C(R35)-;
I является -C(R36)-;
J является -C(R37)-; и
K является -C(R38)-
3. Соединение, имеющее структурную формулу (IIIb1):
Figure 00000568

где
A является водородом, алкилом, замещенным алкилом, арилом, замещенным арилом, арилалкилом, замещенным арилалкилом, ацилом, замещенным ацилом, гетероалкилом, замещенным гетероалкилом, гетероарилом, замещенным гетероарилом, гетероарилалкилом, замещенным гетероарилалкилом, -CN, -OR9, -NO2, -S(O)cR9, -NHOR9, -NR9COR10, -NR9R10, -CONR9R10, -CO2R9 или -NR9CO2R10;
R17 является водородом, алкилом, замещенным алкилом, арилалкилом или замещенным арилалкилом;
X1 является -СН2-, -O-, -NR9-, -S-, -S(O)- или -S(O)2-;
X2 является алкиленом, замещенным алкиленом, гетероалкиленом или замещенным гетероалкиленом;
m равно 0 или 1;
Y1 является гетероарилом, замещенным гетероарилом, циклогетероалкилом, замещенным циклогетероалкилом или
Figure 00000569

X3 и X5 независимо являются ковалентной связью, -O- или -NR9-;
X4 является O, NR9, N-OR9 или S;
Rx является галогеном, -NO2, -CN, -OH, -NH2, алкилом, замещенным алкилом, арилом, замещенным арилом, арилалкилом, замещенным арилалкилом, гетероалкилом, замещенным гетероалкилом, гетероарилом, замещенным гетероарилом, гетероарилалкилом или замещенным гетероарилалкилом;
n равно 0, 1, 2 или 3;
Ry является водородом, алкилом, замещенным алкилом, арилом, замещенным арилом, арилалкилом, замещенным арилалкилом, гетероалкилом, замещенным гетероалкилом, гетероарилом, замещенным гетероарилом, гетероарилалкилом или замещенным гетероарилалкилом, -NR9R10; и
каждый R9 и R10 независимо является водородом, алкилом, замещенным алкилом, арилом, замещенным арилом, арилалкилом, замещенным арилалкилом, гетероалкилом, замещенным гетероалкилом, гетероарилом, замещенным гетероарилом, гетероарилалкилом или замещенным гетероарилалкилом;
при условии, что если X1 является -O- или -S-, и m равно нулю; то X3 не является -O-.
4. Соединение по п.3, где
X1 является -СН2-; и
Y1 является
Figure 00000570

где
X1 является -O-, -NR9- или -S-;
m равно 0 или 1, и
Y1 является циклогетероалкилом или замещенным циклогетероалкилом;
или
где
X1 является -O-, -NR9- или -S-;
m равно 1, и
Y1 является
Figure 00000571
5. Соединение по любому из пп.3 или 4, где
X2 является метиленом, этиленом, пропиленом, изо-пропиленом, бутиленом, изо-бутиленом, втор-бутиленом, пентиленом, гексиленом, гептиленом, диметилэтиленом, метилциклопропиленом, циклопропилметиленом, этениленом, пропениленом или бутениленом.
6. Соединение по п.3, где
а) Y1 является пиперидинилом, замещенным пиперидинилом/ тетрагидрофуранилом, замещенным тетрагидрофуранилом, тетрагидропиранилом, замещенным тетрагидропиранилом, дигидрофуранилом, замещенным дигидрофуранилом, пирролидинилом, замещенным пирролидинилом, оксетанилом, замещенным оксетанилом, сахаридным кольцом или его производным, замещенным сахаридным кольцом или его производным;
или где
б) Y1 является пиридинилом, замещенным пиридинилом, пирролилом, замещенным пирролилом, фуранилом, замещенным фуранилом, пиразолилом, замещенным пиразолилом, изоксазолилом, замещенным изоксазолилом, оксазолилом и замещенным оксазолилом;
или где
в) замещенный циклогетероалкил содержит один или более заместителей, выбранных из группы, включающей алкил, замещенный алкил, арил, замещенный арил, арилалкил, замещенный арилалкил, ацил, замещенный ацил, гетероалкил, замещенный гетероалкил, гетероарил, замещенный гетероарил, гетероарилалкил, замещенный гетероарилалкил, -CN, -OR9, -NO2, -S(O)cR9, -NHOR9, -NR9COR10, -NR9R10, -CONR9R10, -CO2R9 и -NR9CO2R10;
или где
г) Y1 является
Figure 00000572

или где
д) -X3-C(X4)-X5- является -C(O)-, -C(O)-NH-, -NH-C(O)-, -NH-C(O)-NH-, -C(O)-O-, -O-C(O)-, -O-C(O)-O-, -NH-C(O)-O-, -O-C(O)-NH-, -C(NH)-, -C(NH)-NH-, -NH-C(NH)-, -NH-C(NH)-NH-, -C(NH)-O-, -O-C(NH)-, -O-C(NH)-O, -NH-C(NH)-O-, -O-C(NH)-NH-, -C(N-OH)- или -C(S)-;
или где
е) A является водородом, алкилом, замещенным алкилом или -NR9R10;
R17 является водородом; и
Y1 является пиперидинилом, замещенным пиперидинилом, тетрагидрофуранилом, замещенным тетрагидрофуранилом, тетрагидропиранилом, замещенным тетрагидропиранилом, дигидрофуранилом, замещенным дигидрофуранилом, пирролидинилом, замещенным пирролидинилом, оксетанилом, замещенным оксетанилом, моносахаридным кольцом, замещенным моносахаридным кольцом, пиридинилом, замещенным пиридинилом, пирролилом, замещенным пирролилом, фуранилом, замещенным фуранилом, пиразолилом, замещенным пиразолилом, изоксазолилом, замещенным изоксазолилом, оксазолилом или замещенным оксазолилом;
или где
ж) A является водородом, алкилом, замещенным алкилом или -NR9R10;
R17 является водородом;
Y1 является -X3-C(X4)-X5-; и
-X3-С(Х4)-Х5- является -C(O)-, -C(O)-NH-, -NH-C(O)-, -NH-C(O)-NH-, -C(O)-O-, -O-C(O)-, -O-C(O)-O-, -NH-C(O)-O-, -O-C(O)-NH-, -C(NH)-, -C(NH)-NH-, -NH-C(NH)-, -NH-C(NH)-NH-, -C(NH)-O-, -O-C(NH)-, -O-C(NH)-O-, -NH-C(NH)-O-, -O-C(NH)-NH-, -S(O)2-, -NH-S(O)2-, -S(O)2-NH-, -O-S(O)2-, -S(O)2-O-, -C(N-OH)- или -C(S)-.
7. Соединение по п.1 или 3, имеющее структурную формулу, выбранную из группы, включающей
Figure 00000573

Figure 00000574

Figure 00000575

Figure 00000576


Figure 00000578

Figure 00000579

Figure 00000580

Figure 00000581

Figure 00000582

Figure 00000583

Figure 00000584

Figure 00000585

Figure 00000586

Figure 00000587

Figure 00000588

Figure 00000589

Figure 00000590

Figure 00000591

Figure 00000592

Figure 00000593

Figure 00000594

Figure 00000595

Figure 00000596

Figure 00000597

Figure 00000598

Figure 00000599

Figure 00000600

Figure 00000601

Figure 00000602

Figure 00000603

Figure 00000604

Figure 00000605

Figure 00000606

Figure 00000607

Figure 00000608

Figure 00000609

Figure 00000610

Figure 00000611

Figure 00000612

Figure 00000613

Figure 00000614

Figure 00000615

Figure 00000616

Figure 00000617

Figure 00000618

Figure 00000619

Figure 00000620

Figure 00000621

Figure 00000622

Figure 00000623

Figure 00000624

Figure 00000625

Figure 00000626

Figure 00000627

Figure 00000628

Figure 00000629

Figure 00000630

Figure 00000631

Figure 00000632

Figure 00000633

Figure 00000634

Figure 00000635

Figure 00000636

Figure 00000637

Figure 00000638

Figure 00000639

Figure 00000640

Figure 00000641

Figure 00000642

Figure 00000643

Figure 00000644

Figure 00000645

Figure 00000646

Figure 00000647

Figure 00000648

Figure 00000649

Figure 00000650

Figure 00000651

Figure 00000652

Figure 00000653

Figure 00000654

Figure 00000655

Figure 00000656

Figure 00000657

Figure 00000658

Figure 00000659

Figure 00000660

Figure 00000661

Figure 00000662

Figure 00000663

Figure 00000664

Figure 00000665

Figure 00000666

Figure 00000667

или его таутомер, соль, сольват и/или его сложный эфир.
8. Проглатываемая композиция, содержащая соединение, имеющее структурную формулу (IIIb) по п.1 или структурную формулу (IIIb1) по п.3, или его таутомер, соль, сольват и/или его сложный эфир.
9. Проглатываемая композиция по п.8, выбранная из группы, включающей пищевой продукт или напиток, несъедобный продукт, фармацевтическую композицию и их сочетание.
10. Проглатываемая композиция по п.9, где пищевой продукт или напиток выбирают из группы, включающей категорию супов; категорию высушенных бакалейных товаров; категорию напитков; категорию готовых блюд; категорию консервированных продуктов; категорию замороженных бакалейных товаров; категорию охлажденных бакалейных товаров; категорию закусок; категорию хлебобулочных изделий; категорию кондитерских изделий; категорию молочных продуктов; категорию мороженого; категорию заменителей пищи; категорию макарон и лапши; категорию соусов, заправок, приправ; категорию детского питания; категорию спредов; категорию сладких покрытий, глазировки или глазури; и их сочетание.
11. Проглатываемая композиция по п.9, где несъедобный продукт выбирают из группы, включающей нутрицевтики и пищевые добавки, безрецептурные лекарственные средства, продукты по уходу за полостью рта и косметические продукты.
12. Проглатываемая композиция по п.8, где соединение, имеющее структурную формулу (IIIb) по п.1 или структурную формулу (IIIb1) по п.3, или таутомер, соль, сольват и/или его сложный эфир, находится в количестве, улучшающем сладкий вкус; предпочтительно, где количество, улучшающее сладкий вкус, не является терапевтически эффективным количеством.
13. Проглатываемая композиция по любому одному из пп.8, 9, 10, 11 или 12, также содержащая, по крайней мере, один подсластитель.
14. Проглатываемая композиция по п.13, где соединение, улучшающее сладкий вкус, выбирают из группы, включающей сахарозу, фруктозу, глюкозу, галактозу, маннозу, лактозу, тагатозу, мальтозу, кукурузный сироп (включая кукурузный сироп с высоким содержанием фруктозы), D- триптофан, глицин, эритритол, изомальт, лактит, маннит, сорбит, ксилит, мальтодекстрин, мальтит, изомальт, гидрированный сироп глюкозы (HGS), гидрированный гидролизат крахмала (HSH), стевиозид, ребаудиозид А и другие сладкие гликозиды на основе стевии, карелам, другие подсластители на основе гуанидина, сахарин, ацесульфам К, цикламат, сукралозу, алитам, могросид, неотам, аспартам, другие производные аспартама и их сочетания.
15. Проглатываемая композиция по п.13, где, по крайней мере, одно соединение, улучшающее сладкий вкус, содержит
по крайней мере, один натуральный подсластитель; и
по крайней мере, один искусственный или синтезированный подсластитель.
16. Проглатываемая композиция по п.15, где природным подсластителем является сахаридный подсластитель, натуральный сахар или полусинтетический подсластитель на основе «сахарного спирта».
17. Проглатываемая композиция по п.16, где искусственным или синтезированным подсластителем является некалорийная сладкая вкусовая добавка, сладкая вкусовая добавка с пониженной калорийностью или нецелевая калорийная сладкая вкусовая добавка.
18. Проглатываемая композиция по п.16, где природный подсластитель выбирают из группы, включающей сахарозу, фруктозу, глюкозу, тагатозу, мальтозу, галактозу, маннозу, лактозу, глицин, кукурузный сироп или другие сиропы или концентраты подсластителя, полученных из натуральных фруктов и растительных источников, эритритол, изомальт, лактит, маннит, сорбит, ксилит, мальтодекстрин и могрозид.
19. Проглатываемая композиция по п.17, где искусственный или синтезированный подсластитель выбирают из группы, включающей аспартам, сахарин, ацесульфам-К, цикламат, сукралозу, алитам, аспартам, неотам, производные аспартама, D-триптофан, гидрированный сироп глюкозы (HGS), гидрированный гидролизат крахмала (HSH), стевиозид, ребаудиозид А, сладкие гликозиды на основе стевии, карелам и подсластители на основе гуанидина.
20. Подслащивающая композиция, содержащая соединение, имеющее структурную формулу (IIIb) по п.1 или структурную формулу (IIIb1) по п.3, или его таутомер, соль, сольват и/или его сложный эфир.
21. Способ улучшения сладкого вкуса съедобной композиции, включающий взаимодействие съедобной композиции или ее предшественников с соединением, имеющим структурную формулу (IIIb) по п.1, структурную формулу (IIIb1) по п.3, или его таутомером, солью, сольватом и/или сложным эфиром.
22. Способ улучшения сладкого вкуса съедобной композиции, включающий взаимодействие съедобной композиции или ее предшественников с подслащивающей композицией по п.20.
23. Проглатываемая композиция по п.8, которая представлена в пищевом продукте или напитке.
24. Проглатываемая композиция по п.8, которая представлена в твердом или жидком концентрате.
RU2009148316/15A 2007-06-08 2008-06-03 Модулирование хемосенсорных рецепторов и связанных с ними лигандов RU2510503C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/760,592 US9603848B2 (en) 2007-06-08 2007-06-08 Modulation of chemosensory receptors and ligands associated therewith
US11/760,592 2007-06-08
US11/836,074 US7928111B2 (en) 2007-06-08 2007-08-08 Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US11/836,074 2007-08-08
US2741008P 2008-02-08 2008-02-08
US61/027,410 2008-02-08
PCT/US2008/065650 WO2008154221A2 (en) 2007-06-08 2008-06-03 Modulation of chemosensory receptors and ligands associated therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2013153359/15A Division RU2586282C2 (ru) 2007-06-08 2008-06-03 Модулирование хемосенсорных рецепторов и связанных с ними лигандов

Publications (2)

Publication Number Publication Date
RU2009148316A RU2009148316A (ru) 2011-07-20
RU2510503C2 true RU2510503C2 (ru) 2014-03-27

Family

ID=40130430

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2013153359/15A RU2586282C2 (ru) 2007-06-08 2008-06-03 Модулирование хемосенсорных рецепторов и связанных с ними лигандов
RU2009148316/15A RU2510503C2 (ru) 2007-06-08 2008-06-03 Модулирование хемосенсорных рецепторов и связанных с ними лигандов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2013153359/15A RU2586282C2 (ru) 2007-06-08 2008-06-03 Модулирование хемосенсорных рецепторов и связанных с ними лигандов

Country Status (19)

Country Link
US (3) US7928111B2 (ru)
EP (3) EP2062050B1 (ru)
JP (4) JP2010531437A (ru)
CN (3) CN101779124B (ru)
AR (1) AR071637A1 (ru)
AU (1) AU2008262109B2 (ru)
BR (1) BRPI0812436B1 (ru)
CA (2) CA3030265A1 (ru)
CL (1) CL2008001665A1 (ru)
CO (1) CO6331432A2 (ru)
DK (1) DK2062050T3 (ru)
ES (1) ES2732935T3 (ru)
MX (2) MX371288B (ru)
MY (2) MY187157A (ru)
RU (2) RU2586282C2 (ru)
SA (2) SA113340431B1 (ru)
SG (1) SG182179A1 (ru)
TW (4) TWI579287B (ru)
WO (1) WO2008154221A2 (ru)

Families Citing this family (270)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
DK2004654T3 (da) 2006-04-04 2013-07-22 Univ California Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
US9603848B2 (en) * 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) * 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101660050B1 (ko) 2008-01-04 2016-09-26 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
ES2475206T3 (es) 2008-02-01 2014-07-10 Takeda Pharmaceutical Company Limited Derivados de oxima como inhibidores de HSP90
EP2247196B1 (en) * 2008-02-06 2014-11-26 Senomyx, Inc. Sweetener compositions and methods of making them
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP3009436B1 (en) 2008-07-08 2019-06-05 Intellikine, LLC Kinase inhibitors and methods of use
WO2010014813A2 (en) 2008-07-31 2010-02-04 Senomyx, Inc. Compositions comrpising sweetness enhancers and methods of making them
US8586733B2 (en) 2008-07-31 2013-11-19 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
UA103195C2 (ru) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Производные пурина для применения в лечении аллергий, воспалительных и инфекционных заболеваний
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
ES2570429T3 (es) 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
CN102227424B (zh) 2008-10-23 2013-08-14 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
AU2009308232B2 (en) 2008-10-23 2016-02-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
AR076341A1 (es) 2009-04-20 2011-06-01 Elcelyx Therapeutics Inc Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011075747A1 (en) * 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2371823A1 (de) 2010-04-01 2011-10-05 Bayer CropScience AG Cyclopropyl-substituierte Phenylsulfonylamino(thio)carbonyltriazolinone, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
SG184156A1 (en) 2010-04-02 2012-10-30 Senomyx Inc Sweet flavor modifier
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
RU2576451C2 (ru) * 2010-08-12 2016-03-10 Синомикс, Инк. Способ улучшения стабильности усилителей сладкого вкуса и композиция, содержащая стабилизированный усилитель сладкого вкуса
US20130281394A1 (en) * 2010-10-19 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
KR20140114736A (ko) * 2010-10-19 2014-09-29 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
BR112013009636A2 (pt) * 2010-10-19 2016-07-19 Elcelyx Therapeutics Inc terapias à base de ligante de receptor quimiossensorial
EP2629609A4 (en) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
KR101888658B1 (ko) * 2011-04-15 2018-08-14 에스에프씨 주식회사 신규한 화합물 및 이를 포함하는 유기전계발광소자
WO2012151587A1 (en) * 2011-05-05 2012-11-08 The Coca-Cola Company Methods and formulations for inhibiting degradation of photosensitive sweeteners and sweetener enhancers
CN102816175B (zh) * 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
KR101916928B1 (ko) 2011-07-22 2018-11-08 글락소스미스클라인 엘엘씨 조성물
CN103764630B (zh) 2011-08-12 2017-08-08 赛诺米克斯公司 甜味调节剂
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
KR20140097127A (ko) 2011-09-16 2014-08-06 포비어 파마수티칼스 아닐린 유도체, 그의 제조법 및 그의 치료 용도
JP5914667B2 (ja) 2011-09-22 2016-05-11 ファイザー・インク ピロロピリミジンおよびプリン誘導体
MD20140044A2 (ru) 2011-11-11 2014-08-31 Pfizer Inc. 2-Тиопиримидиноны и их использование для лечения сердечно-сосудистых заболеваний
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
RS61089B1 (sr) 2012-06-13 2020-12-31 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN104603132B (zh) * 2012-08-06 2020-02-21 弗门尼舍公司 甜味调节剂
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
CA2880576A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
WO2014052432A1 (en) * 2012-09-26 2014-04-03 Wm. Wrigley Jr. Company Method of controlling release of sweetness enhancer in chewing gum and gum produced thereby
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX386085B (es) 2012-11-01 2025-03-18 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa
CN102898301A (zh) * 2012-11-12 2013-01-30 陈卫东 一种2-溴-3-氟苯甲酸的制备方法
CN104780924B (zh) 2012-11-20 2016-09-14 葛兰素史克有限责任公司 干扰素诱导剂化合物
PT2922549T (pt) 2012-11-20 2017-09-01 Glaxosmithkline Llc Novos compostos
AU2013348216B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN104883904B (zh) * 2012-12-21 2021-04-06 弗门尼舍有限公司 口味改变组合物
CN104968200B (zh) 2013-02-01 2018-03-06 维尔斯达医疗公司 具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
KR101446680B1 (ko) * 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
CA2903881C (en) 2013-03-15 2021-05-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
RU2543881C1 (ru) * 2013-08-02 2015-03-10 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Хемосенсорный композитный материал для определения катионов меди (ii) и композиция для его получения
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112016007238A2 (pt) 2013-10-07 2017-08-01 Bayer Pharma AG tienouracilcarboxamidas cíclicas e sua utilização
CA2926950C (en) 2013-10-10 2022-10-11 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015164480A1 (en) 2014-04-23 2015-10-29 Incyte Corporation 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
US20150366252A1 (en) * 2014-06-24 2015-12-24 International Flavors & Fragrances Inc. Sweetener enhancers and methods for using the same
CN106456592B (zh) * 2014-06-27 2019-06-18 味之素株式会社 甜味受体拮抗剂
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2963901A1 (en) 2014-11-07 2016-05-12 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AU2016216673B2 (en) 2015-03-04 2017-02-02 Gilead Sciences, Inc. Toll like receptor modulator compounds
CU20170134A7 (es) 2015-05-05 2017-12-08 Pfizer 2-tiopirimidinonas
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
ES2899906T3 (es) 2015-07-06 2022-03-15 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
US10370337B2 (en) 2015-07-29 2019-08-06 Merck, Sharp & Dohme Corp. Oxy-cyanoquinolinone PDE9 inhibitors
WO2017019723A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone pde9 inhibitors
US10370336B2 (en) * 2015-07-29 2019-08-06 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone PDE9 inhibitors
PL3331380T3 (pl) * 2015-08-07 2021-07-19 V. Mane Fils Kompozycja obejmująca związki modulujące smak, ich zastosowanie oraz zawierające je produkty żywnościowe
CA2998469C (en) 2015-09-14 2025-12-09 Twelve Therapeutics, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
SG11201803603WA (en) 2015-10-29 2018-05-30 Senomyx Inc High intensity sweeteners
CN105418609B (zh) * 2015-12-31 2017-06-23 山东大学 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SMT202300155T1 (it) 2016-06-20 2023-07-20 Incyte Corp Forme solide cristalline di un inibitore di bet
BR112018077021A2 (pt) 2016-06-24 2019-04-02 Infinity Pharmaceuticals, Inc. terapias de combinação
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
LT3317260T (lt) 2016-09-21 2020-01-27 Celanese International Corporation Acesulfamo kalio kompozicijos ir jų gamybos būdai
RS62400B1 (sr) 2016-09-21 2021-10-29 Celanese Int Corp Kompozicije acesulfam-kalijuma i postupci za njihovu proizvodnju
RS60987B1 (sr) 2016-09-21 2020-11-30 Celanese Int Corp Kompozicije acesulfam-kalijuma i postupci za njihovu proizvodnju
CN108884064A (zh) 2016-09-21 2018-11-23 国际人造丝公司 乙酰舒泛钾组合物和其生产方法
AU2017376818A1 (en) * 2016-12-13 2019-07-11 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
ES2909086T3 (es) 2017-01-11 2022-05-05 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
KR102664772B1 (ko) 2017-01-23 2024-05-10 노파르티스 아게 칼륨 채널 조절제
CN106966975A (zh) * 2017-03-28 2017-07-21 济南大学 一种改进的由靛红酸酐合成4‑氯‑1氢‑喹啉‑2‑酮‑3‑羧酸甲酯的方法
WO2018181892A1 (ja) * 2017-03-31 2018-10-04 国立大学法人 長崎大学 キノリノン化合物および抗ｒｎａウイルス薬
CN111108213B (zh) 2017-05-03 2024-12-13 弗门尼舍公司 制备高强度甜味剂的方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10604414B2 (en) 2017-06-15 2020-03-31 Energysource Minerals Llc System and process for recovery of lithium from a geothermal brine
EA039417B1 (ru) 2017-08-07 2022-01-25 Родин Терапеутикс, Инк. Бициклические ингибиторы гистондеацетилазы
JP2021014405A (ja) * 2017-10-16 2021-02-12 味の素株式会社 甘味受容体アンタゴニスト
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
BR112021002261A2 (pt) * 2018-08-07 2021-05-04 Firmenich Incorporated 2,2-dióxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-substituídos e formulações e usos dos mesmos
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators
CN109082280B (zh) * 2018-11-05 2020-07-28 宁夏中星显示材料有限公司 一种液晶材料的制备方法
MX2021005219A (es) 2018-11-07 2021-06-18 Firmenich Incorporated Metodos para hacer edulcorantes de alta intensidad.
BR112021008929A2 (pt) 2018-11-07 2021-08-17 Firmenich Incorporated métodos para fazer edulcorantes de alta intensidade
BR112021010842A2 (pt) 2018-12-10 2021-08-24 Ideaya Biosciences, Inc. Derivados de 2-oxoquinazolina como inibidores de metionina adenosiltransferase 2a
CN109602757B (zh) * 2019-01-11 2020-11-17 桂林医学院附属医院 罗汉果苷iie在制备胰蛋白酶抑制剂中的应用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN113271795A (zh) 2019-03-28 2021-08-17 弗门尼舍有限公司 调味料系统
CN113661171B (zh) 2019-04-04 2024-04-12 弗门尼舍有限公司 罗汉果苷化合物及其用途
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
JP2022537613A (ja) 2019-06-28 2022-08-29 フイルメニツヒ ソシエテ アノニム 脂肪ブレンド、そのエマルション、および関連する使用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4025071A1 (en) 2019-09-05 2022-07-13 Firmenich SA Flavanone derivatives and their use as sweetness enhancers
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114793434A (zh) 2019-10-18 2022-07-26 加利福尼亚大学董事会 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物
CN113226058A (zh) 2019-11-11 2021-08-06 弗门尼舍有限公司 姜酚化合物及其作为风味改良剂的用途
CN111018777B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种地喹氯铵的制备方法
CN110963967B (zh) * 2019-11-25 2021-02-12 武汉智顿科技发展有限公司 一种2-甲基-4-氨基喹啉的制备方法
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022009553A2 (pt) 2019-12-13 2022-08-02 Firmenich Incorporated Composições modificadoras de sabor e usos das mesmas
WO2021118864A1 (en) 2019-12-13 2021-06-17 Firmenich Incorporated Taste modifying compositions and uses thereof
KR20220114529A (ko) 2019-12-18 2022-08-17 피르메니히 인코포레이티드 맛 개질 조성물 및 이의 용도
WO2021126569A1 (en) 2019-12-18 2021-06-24 Firmenich Incorporated Taste modifying compositions and uses thereof
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021175751A1 (en) 2020-03-05 2021-09-10 Firmenich Sa 11-oxo-cucurbitanes and their use as flavor modifiers
US20230148641A1 (en) 2020-03-31 2023-05-18 Firmenich Sa Flavor composition
CN114096515B (zh) 2020-04-17 2024-07-26 弗门尼舍有限公司 氨基酸衍生物及其作为风味改良剂的用途
EP4096714B1 (en) 2020-05-22 2026-01-28 Firmenich SA Compositions for reducing salty taste and uses thereof
JP7770328B2 (ja) 2020-06-03 2025-11-14 フイルメニツヒ ソシエテ アノニム 雑味を減らす組成物およびその使用
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2021259945A1 (en) 2020-06-24 2021-12-30 Firmenich Sa Sweetening compositions and uses thereof
CN115551598A (zh) 2020-07-14 2022-12-30 弗门尼舍有限公司 口腔护理产品中的不希望的味道调性的减少
US20230276835A1 (en) 2020-07-24 2023-09-07 Firmenich Incorporated Savory taste enhancement via transmembrane region binding
US20230338247A1 (en) 2020-09-22 2023-10-26 Firmenich Sa Wintergreen flavor compositions free of methyl salicylate
EP4228433A1 (en) 2020-10-13 2023-08-23 Firmenich SA Malonyl steviol glycosides and their comestible use
WO2022090218A1 (en) 2020-10-27 2022-05-05 Firmenich Sa Conjugated diynes and their use as flavor modifiers
JP2023550963A (ja) 2020-11-24 2023-12-06 フィルメニッヒ インコーポレイテッド コク味の増強及び関連するスクリーニング方法
CN115988967A (zh) 2020-11-29 2023-04-18 弗门尼舍有限公司 减少过氧化物异味的组合物及其用途
WO2022136288A1 (en) 2020-12-23 2022-06-30 Firmenich Sa Uses of fat blends and emulsions thereof
EP4251122B1 (en) 2021-01-13 2025-03-12 Firmenich Incorporated Compositions that enhance the cooling effect
US20240074479A1 (en) 2021-02-10 2024-03-07 Firmenich Sa Fiber blends, sweetened fiber blends, and their comestible use
US20240099344A1 (en) 2021-03-09 2024-03-28 Firmenich Sa Hydroxy- and methoxy-substituted flavonoids and their use
US20240114939A1 (en) 2021-03-09 2024-04-11 Firmenich Sa Hydroxy- and methoxy-substituted flavones and their use
US20240099343A1 (en) 2021-04-06 2024-03-28 Firmenich Sa Use of gingerdiol compounds to enhance flavor
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
BR112023020008A2 (pt) 2021-04-15 2023-11-14 Givaudan Sa Composição modificadora de sabor, seu uso, composição adoçada, produtos de bebida e alimentício, bem como método para modificação de sabor de uma composição adoçada
EP4304386A1 (en) 2021-04-26 2024-01-17 Firmenich Incorporated Amide compounds and their use as flavor modifiers
US20240315299A1 (en) 2021-04-26 2024-09-26 Firmenich Incorporated Amide compounds and their use as flavor modifiers
EP4307919A2 (en) 2021-05-11 2024-01-24 Firmenich SA Process of making gingerol compounds and their use as flavor modifiers
WO2022248405A1 (en) 2021-05-24 2022-12-01 Firmenich Sa Flavored fiber blends and their comestible use
CN117479843A (zh) * 2021-05-28 2024-01-30 弗门尼舍公司 增强清凉效果的组合物
JP2024522284A (ja) 2021-05-28 2024-06-13 フィルメニッヒ インコーポレイテッド 清涼効果を増強する組成物
WO2022253681A1 (en) 2021-06-02 2022-12-08 Firmenich Sa Deacetylation process, compositions, and uses thereof
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
JP2024524266A (ja) 2021-06-23 2024-07-05 フイルメニツヒ ソシエテ アノニム ラクターゼを含むフレーバー修飾組成物
WO2023278394A1 (en) 2021-06-28 2023-01-05 Firmenich Incorporated Polycationic salts of phenolic compounds and uses thereof
US20240237690A1 (en) 2021-06-29 2024-07-18 Firmenich Sa Licorice Compounds and Their Use as Flavor Modifiers
WO2023278226A1 (en) 2021-06-29 2023-01-05 Firmenich Incorporated Mogroside compounds and their comestible use
CN118043443A (zh) 2021-09-27 2024-05-14 弗门尼舍公司 香草基醚用于修饰蒸馏酒的风味的用途
EP4362689A1 (en) 2021-09-27 2024-05-08 Firmenich SA Flavor compositions containing iron compounds and their use
AR127359A1 (es) 2021-11-01 2024-01-17 Firmenich & Cie Composición que comprende un nutriente y un modulador del sabor
HRP20251438T1 (hr) 2021-11-02 2026-01-02 Flare Therapeutics, Inc. Inverzni agonisti pparg i njihova upotreba
US20250024871A1 (en) 2021-11-16 2025-01-23 Firmenich Incorporated Amide compounds and their use as flavor modifiers
WO2023107904A1 (en) 2021-12-07 2023-06-15 Firmenich Incorporated Reduction of bitter taste of plant proteins and related assays and screening methods
EP4418872A1 (en) 2021-12-20 2024-08-28 Firmenich SA Encapsulated metal compounds and comestible uses thereof
MX2024006776A (es) 2021-12-23 2024-06-20 Firmenich & Cie Composicion antimicrobiana que tiene colorante encapsulado.
CN118785815A (zh) 2022-03-04 2024-10-15 弗门尼舍有限公司 多甲氧基黄酮类化合物的纯化方法以及由该方法获得的组合物
WO2023172394A1 (en) 2022-03-11 2023-09-14 Firmenich Incorporated Flavanone compounds and their use as flavor modifiers
EP4456737A1 (en) 2022-03-11 2024-11-06 Firmenich Incorporated Amide compounds and their use as flavor modifiers
JP2025510215A (ja) 2022-03-25 2025-04-14 フイルメニツヒ ソシエテ アノニム 脂肪酸アミドおよびそれらの風味改変剤としての使用
CN119212569A (zh) 2022-03-28 2024-12-27 弗门尼舍有限公司 非动物蛋白组合物及其用途
CA3254517A1 (en) 2022-04-06 2023-10-12 Firmenich Incorporated TASTE MODIFICATION COMPOUNDS AND THEIR USES
EP4492989A1 (en) 2022-05-16 2025-01-22 Firmenich Incorporated Unsaturated fatty acids and their use to modify taste
US20250275559A1 (en) 2022-05-16 2025-09-04 Firmenich Incorporated Saturated fatty acids and their use to modify taste
EP4532470A1 (en) 2022-05-25 2025-04-09 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US20250344736A1 (en) 2022-06-03 2025-11-13 Firmenich Sa Fat reduction in non-animal protein compositions
EP4507521A1 (en) 2022-06-14 2025-02-19 Firmenich SA Polyelectrolyte complexes of proteins and uses thereof
CN119421642A (zh) 2022-06-24 2025-02-11 弗门尼舍有限公司 味道修饰组合物及其用途
JP2025520966A (ja) 2022-07-07 2025-07-03 フィルメニッヒ インコーポレイテッド 冷却効果を増強する組成物
EP4514142A1 (en) 2022-08-22 2025-03-05 Firmenich SA Gel compositions and their use in seafood analogue products
EP4577059A1 (en) 2022-10-26 2025-07-02 Firmenich Incorporated Taste modifying compositions and uses thereof
WO2024089025A1 (en) 2022-10-26 2024-05-02 Firmenich Sa Extrusion methods and flavored products formed thereby
WO2024094523A1 (en) 2022-11-01 2024-05-10 Firmenich Sa Low-calorie composition for flavor modification
WO2024137186A1 (en) 2022-12-23 2024-06-27 Firmenich Incorporated Beta-cyclodextrin and its use to modify flavor
US20260013537A1 (en) 2023-01-09 2026-01-15 Firmenich Sa Use of plant fibers to improve flavor of fermented products
EP4665157A1 (en) 2023-02-15 2025-12-24 Firmenich SA Thermoresponsive gel composition and uses thereof
EP4630413A1 (en) 2023-02-25 2025-10-15 Firmenich Incorporated Flavanone compounds and their use as flavor modifiers
EP4683521A1 (en) 2023-03-23 2026-01-28 Firmenich Incorporated Use of vanillyl ethers to modify flavor
EP4661689A1 (en) 2023-03-24 2025-12-17 Firmenich SA Microparticles containing algal proteins and uses thereof
WO2024205979A1 (en) 2023-03-29 2024-10-03 Firmenich Incorporated Use of fatty acids to modify flavor
WO2024208837A1 (en) 2023-04-04 2024-10-10 Firmenich Sa Polysaccharide compositions and their comestible use
WO2024227789A1 (en) 2023-05-03 2024-11-07 Firmenich Sa Encapsulated phenolic compounds and their comestible use
WO2024251755A1 (en) 2023-06-09 2024-12-12 Dsm-Firmenich Ag Compositions for reducing off notes and uses thereof
EP4480319A1 (en) 2023-06-22 2024-12-25 DSM-Firmenich AG Granola cluster
WO2025049939A1 (en) * 2023-09-01 2025-03-06 Memorial Sloan-Kettering Cancer Center Selective androgen receptor modulator based radiopharmaceuticals for imaging androgen receptor
WO2025067974A1 (en) 2023-09-26 2025-04-03 Firmenich Sa Vegan cheese compositions and methods of making the same
WO2025073683A1 (en) 2023-10-04 2025-04-10 Firmenich Sa Flavanone compounds and their use as flavor modifiers
WO2025125286A1 (en) 2023-12-13 2025-06-19 Firmenich Sa Biopolymer compositions and their use in foamed compositions
WO2025132821A1 (en) 2023-12-19 2025-06-26 Firmenich Sa Comestible products having high fiber and low sugar
WO2025132803A1 (en) 2023-12-20 2025-06-26 Firmenich Sa 3-hydroxybenzoic acid and its use as a flavor modifier
WO2025172491A1 (en) 2024-02-16 2025-08-21 Givaudan Sa Compositions comprising honey truffle protein
WO2025191050A1 (en) 2024-03-15 2025-09-18 Firmenich Sa Lipid particles and their comestible use
WO2025221883A1 (en) 2024-04-17 2025-10-23 Firmenich Incorporated Taste modifying compositions and uses thereof
WO2025230968A1 (en) 2024-04-30 2025-11-06 Firmenich Incorporated Ketone compounds for enhancing alcohol perception
WO2026012986A1 (en) 2024-07-09 2026-01-15 Givaudan Sa Flavor compositions comprising methyl n-[3-(3-hydroxy-4-methoxyphenyl)propyl]aspartylphenylalaninat

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278532A (en) * 1964-07-06 1966-10-11 Sandoz Ag Dioxybenzothiadiazines
US3843804A (en) * 1971-03-10 1974-10-22 Int Flavors & Fragrances Inc Novel flavoring compositions and processes
US20060134693A1 (en) * 2001-07-06 2006-06-22 Guy Servant Olfactory cyclic nucleotide-gated channel cell-based assays to identify T1R and T2R taste modulators
US20070104709A1 (en) * 2003-08-06 2007-05-10 Xiaodong Li T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB812366A (en) * 1955-08-18 1959-04-22 Wellcome Found Improvements in and relating to derivatives of pyrimidine and the preparation thereof
DE1932402C3 (de) * 1969-06-26 1981-09-03 Sandoz-Patent-GmbH, 7850 Lörrach 1-Isopropyl-4-phenyl-3,4-dihydro-2(1H)chinazolinonderivate und deren Weiterverarbeitung zu 1-Isopropyl-4-phenyl-2(1H)chinazolinonen
US3792036A (en) * 1970-01-07 1974-02-12 Ciba Geigy Corp Pteridine-glycosides
US3857972A (en) 1971-03-10 1974-12-31 Int Flavors & Fragrances Inc Flavoring with an oxocyclic pyrimidine
LU64388A1 (ru) * 1971-12-02 1973-07-16
FI54312C (fi) 1972-05-09 1978-11-10 Sumitomo Chemical Co Foerfarande foer framstaellning av tieno-(2,3-d)pyrimidinderivat med avsoendring av urinsyra i urin utoekande
JPS4981390A (ru) * 1972-12-14 1974-08-06
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3960860A (en) 1973-01-08 1976-06-01 International Flavors & Fragrances Inc. 2-Methyl-5,7-dihydrothieno-[3,4d]-pyrimidine
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2503736A1 (de) * 1975-01-30 1976-08-05 Bayer Ag Verfahren zur herstellung von 2-oxo- 1,2-dihydro-chinazolinen
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
ES472163A1 (es) 1978-07-28 1979-03-16 Consejo Superior Investigacion Ÿun nuevo procedimiento para la obtencion de 5,5-dioxido de 7-amino-2h-4h-vic-triazolo (4,5-c) (1,2,6) tiadiazinaÿ
IE51802B1 (en) * 1979-12-03 1987-04-01 Fujisawa Pharmaceutical Co Quinazoline derivatives,processes for their preparation and pharmaceutical compositions containing them
JPS5951290A (ja) * 1982-09-14 1984-03-24 Dai Ichi Seiyaku Co Ltd ベンゾチエノイミダゾピリミジンジオン化合物
US4617392A (en) * 1983-09-29 1986-10-14 Ortho Pharmaceutical Corporation 4-alkyl-5,6-methylenedioxy-2-1[H]-quinazolinones useful as cardiotonic agents
ES531159A0 (es) 1984-03-30 1985-09-01 Consejo Superior Investigacion Procedimiento para la preparacion de aminociclotiadiazinas
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4672116A (en) * 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
GB8613200D0 (en) * 1986-05-30 1986-07-02 Ici Plc Heterocyclic compounds
US4960870A (en) 1987-02-11 1990-10-02 Ciba-Geigy Corporation Heavy metal complex azo dyes containing a benzothiophene-1,1-dioxide, 2,1-benzothiazine-2,2-dioxide, 1,4-benzothiazine-1,1-dioxide or thienopyridine-1,1-dioxide coupling component
US5380541A (en) * 1987-08-07 1995-01-10 Tate & Lyle Public Limited Company Sucralose compositions
JPH01197760A (ja) * 1988-02-02 1989-08-09 Konica Corp 電子写真感光体
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JPH04128276A (ja) * 1990-09-19 1992-04-28 Pfizer Pharmaceut Co Ltd アミノベンゾサルタム誘導体およびその用途
US5504095A (en) * 1990-09-19 1996-04-02 Pfizer Inc. Aminobenzosultam derivatives as lipoxygenase inhibitors
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
KR970010069B1 (ko) 1992-08-24 1997-06-20 주식회사 럭키 신규 세팔로스포린계 항생제 및 이의 제조방법
JPH06192099A (ja) * 1992-10-07 1994-07-12 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
ZA962078B (en) 1995-03-14 1996-09-25 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
WO1996028205A1 (en) 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6013650A (en) * 1996-03-14 2000-01-11 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
KR100220953B1 (ko) 1996-12-31 1999-10-01 김영환 아미드 또는 이미드를 도입한 ArF 감광막 수지
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US5990117A (en) 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
WO2000071524A1 (en) 1999-05-19 2000-11-30 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
MXPA02009843A (es) 2000-04-07 2004-09-06 Senomyx Inc Receptores t2r del sabor y genes que codifican para los mismos.
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7368285B2 (en) 2001-03-07 2008-05-06 Senomyx, Inc. Heteromeric umami T1R1/T1R3 taste receptors and isolated cells that express same
EP2293067B1 (en) 2001-06-26 2016-04-20 Senomyx, Inc. T1R hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
CA2452716C (en) * 2001-07-03 2012-06-26 The Regents Of The University Of California Mammalian sweet and amino acid heterodimeric taste receptors
WO2003022214A2 (en) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
CN100384422C (zh) * 2001-10-12 2008-04-30 爱克加股票上市公司 包含金属离子螯合剂的抗微生物组合物
AU2002350315B2 (en) * 2001-12-14 2008-05-22 Merck Frosst Canada Ltd Quinolinones as prostaglandin receptor ligands
WO2003055866A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP1496896A4 (en) * 2002-04-08 2007-10-31 Merck & Co Inc AKT INHIBITORS EFFECT
AU2003261354A1 (en) 2002-08-02 2004-02-23 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
JP2004137270A (ja) * 2002-09-26 2004-05-13 Nippon Nohyaku Co Ltd 新規除草剤、その使用方法、新規置換チエノピリミジン誘導体及びその中間体並びにそれらの製造方法
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
CN1764381A (zh) * 2003-03-27 2006-04-26 麦克公司 用于酪氨酸激酶抑制剂的制剂
EP1637532A1 (en) * 2003-04-25 2006-03-22 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivative
EP1631266B1 (en) * 2003-05-13 2011-03-16 DePuy Spine, Inc. A method of treating degenerative disc disease
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7541158B2 (en) * 2004-04-14 2009-06-02 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
US20060045953A1 (en) 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
WO2006076102A2 (en) * 2004-12-10 2006-07-20 The Regents Of The University Of California Fluorescent nucleoside analogs that mimic naturally occurring nucleosides
JP2008524134A (ja) 2004-12-17 2008-07-10 エフ．ホフマン−ラ ロシュ アーゲー Ｇａｂａ−ｂアロステリックエンハンサーとしてのチエノ−ピリジン誘導体
MY158077A (en) 2005-02-04 2016-08-30 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions
JP2008530017A (ja) 2005-02-04 2008-08-07 セノミックス インコーポレイテッド 食料用組成物のための風味調整剤として連結された有機部分を含む分子
WO2006113422A2 (en) * 2005-04-13 2006-10-26 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Human sweet and umami taste receptor variants
WO2006113432A2 (en) * 2005-04-14 2006-10-26 Smithkline Beecham Corporation Compounds, compositions and methods
JP2007007591A (ja) 2005-07-01 2007-01-18 Mikuni Corp 電解水及びその製造方法
WO2007030582A2 (en) * 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
WO2007047988A2 (en) 2005-10-20 2007-04-26 Senomyx, Inc. Chimeric human sweet-umami and umami-sweet taste receptors
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
JP2009520784A (ja) 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ キナゾリン誘導体、その製造方法および抗癌剤としてのその使用
AR059751A1 (es) 2006-03-10 2008-04-23 Shell Int Research Composiciones de combustible diesel
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009006722A1 (en) 2007-07-12 2009-01-15 Mehrzad Gomari Paper-free local flyer advertising (a technology method of localized internet advertising)
US8586733B2 (en) 2008-07-31 2013-11-19 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278532A (en) * 1964-07-06 1966-10-11 Sandoz Ag Dioxybenzothiadiazines
US3843804A (en) * 1971-03-10 1974-10-22 Int Flavors & Fragrances Inc Novel flavoring compositions and processes
US20060134693A1 (en) * 2001-07-06 2006-06-22 Guy Servant Olfactory cyclic nucleotide-gated channel cell-based assays to identify T1R and T2R taste modulators
US20070104709A1 (en) * 2003-08-06 2007-05-10 Xiaodong Li T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GOYA, P. et al. Aminopyrido[2,3-c][1,2,6]thiadiazine 2,2-dioxides: synthesis and physico-chemical properties Chemica Scripta, 1986, 26(4), pp.607-611. *
GOYA, P. et al. Synthesis and physico-chemical properties of 7-oxopyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. Liebigs Annalen der Chemie, 1988, No.2, pp 121-124. *
GOYA, P. et al. Synthesis of 2S-dioxoisosteres of purine and pyrimidine nucleosides IV. Selective glycosylation of 4-amino-5H-imidazo[4,5-c]-1,2,6-thiadiazine 2,2-dioxide. Nucleosides & Nucleotides, 1987, 6(3), pp.631-642. *
KEITH С.С. BANCROFT et al. Synthesis and reduction of some 1H-2,1,3-benzothiadiazin-4(3H)one 2,2-dioxides. Journal of Heterocyclic chemistry, 15(8), 1978, pp.1521-1523. *
MARTINEZ, ANA et al. Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis. Journal of Medicinal Chemistry, 2000, 43(17), pp.3218-3225. *
WRIGHT, JOHN B. Synthesis of 2,1,3-benzothiadiazine 2,2-dioxides and 1,2,3-benzoxathiazine 2,2-dioxides. Journal of Organic Chemistry, 1965, 30(11), pp.3960-3962. *
БЕЛИКОВ В.Г. Фармацевтическая химия. - М.: Высшая школа, 1993, с.43-47. *
БЕЛИКОВ В.Г. Фармацевтическая химия. - М.: Высшая школа, 1993, с.43-47. GOYA, P. et al. Synthesis of 2S-dioxoisosteres of purine and pyrimidine nucleosides IV. Selective glycosylation of 4-amino-5H-imidazo[4,5-c]-1,2,6-thiadiazine 2,2-dioxide. Nucleosides & Nucleotides, 1987, 6(3), pp.631-642. GOYA, P. et al. Synthesis and physico-chemical properties of 7-oxopyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. Liebigs Annalen der Chemie, 1988, №2, pp 121-124. GOYA, P. et al. Aminopyrido[2,3-c][1,2,6]thiadiazine 2,2-dioxides: synthesis and physico-chemical properties Chemica Scripta, 1986, 26(4), pp.607-611. KEITH С.С. BANCROFT et al. Synthesis and reduction of some 1H-2,1,3-benzothiadiazin-4(3H)one 2,2-dioxides. Journal of Heterocyclic chemistry, 15(8), 1978, pp.1521-1523. MARTINEZ, ANA et al. Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis. Journal of Medicinal Chemistry, 2000, 43(17), pp.3218-3225 *

Also Published As

Publication number Publication date
RU2013153359A (ru) 2015-06-10
EP2062050B1 (en) 2016-05-18
AR071637A1 (es) 2010-07-07
MY187157A (en) 2021-09-06
EP2573559B1 (en) 2019-03-13
JP6622353B2 (ja) 2019-12-18
CA2687453C (en) 2019-03-05
CO6331432A2 (es) 2011-10-20
CN101779124B (zh) 2017-12-12
WO2008154221A3 (en) 2009-02-19
CA3030265A1 (en) 2008-12-18
SA08290349B1 (ar) 2013-08-27
US20080306053A1 (en) 2008-12-11
TWI673265B (zh) 2019-10-01
JP2010531437A (ja) 2010-09-24
CN101779124A (zh) 2010-07-14
JP2014001241A (ja) 2014-01-09
CN107365319A (zh) 2017-11-21
EP2062050A2 (en) 2009-05-27
CN110115365A (zh) 2019-08-13
US20140235623A1 (en) 2014-08-21
DK2062050T3 (en) 2016-08-29
SA113340431B1 (ar) 2018-07-04
US9181276B2 (en) 2015-11-10
TW200902539A (en) 2009-01-16
AU2008262109B2 (en) 2013-12-05
MY162619A (en) 2017-06-30
TWI579287B (zh) 2017-04-21
RU2009148316A (ru) 2011-07-20
MX371288B (es) 2020-01-24
RU2586282C2 (ru) 2016-06-10
TWI569733B (zh) 2017-02-11
CL2008001665A1 (es) 2008-10-24
JP2018154639A (ja) 2018-10-04
BRPI0812436A2 (pt) 2014-10-29
JP6360098B2 (ja) 2018-07-18
EP2568287A3 (en) 2013-07-17
EP2573559A1 (en) 2013-03-27
WO2008154221A2 (en) 2008-12-18
EP2062050A4 (en) 2009-11-11
ES2732935T3 (es) 2019-11-26
AU2008262109A1 (en) 2008-12-18
BRPI0812436B1 (pt) 2023-12-26
CN107365319B (zh) 2020-10-27
MX2009013380A (es) 2010-03-01
EP2568287A2 (en) 2013-03-13
US8541421B2 (en) 2013-09-24
AU2008262109A2 (en) 2010-01-28
TW201700463A (zh) 2017-01-01
CA2687453A1 (en) 2008-12-18
TW201945365A (zh) 2019-12-01
US20110230502A1 (en) 2011-09-22
JP5931033B2 (ja) 2016-06-08
US7928111B2 (en) 2011-04-19
SG182179A1 (en) 2012-07-30
JP2017008027A (ja) 2017-01-12
TW201444806A (zh) 2014-12-01

Similar Documents

Publication Publication Date Title
RU2510503C2 (ru) Модулирование хемосенсорных рецепторов и связанных с ними лигандов
AU2019200938B2 (en) Novel triterpene-glycosides as sweeteners or sweetener enhancers
AU2011213602B2 (en) Solubility enhanced terpene glycoside(s)
JP5330380B2 (ja) 甘味増強剤、甘味が増強された甘味料組成物、これらの配合方法および使用方法
JP2011520452A (ja) 改善された経時プロファイル及び／又はフレーバープロファイルを有する天然及び／又は合成高甘味度甘味料組成物、これらの配合方法、および使用
JP2010508823A (ja) 長鎖第一級脂肪族飽和アルコールを有する高甘味度甘味料組成物及びこれにより甘味を付与された組成物
WO2009108680A2 (en) Rebaudioside a derivative products and methods for making
EP4307921A1 (en) Amide compounds and their use as flavor modifiers
JP2025131751A (ja) フラバノン誘導体及び甘味増強剤としてのフラバノン誘導体の使用
CN117255626A (zh) 酰胺化合物及其作为风味修饰剂的用途
CN113423716A (zh) 罗汉果苷化合物及其用途
CN118251134A (zh) 酰胺化合物及其作为风味修饰剂的用途
CN117279520A (zh) 酰胺化合物及其作为风味修饰剂的用途
US20230345986A1 (en) Conjugated diynes and their use as flavor modifiers
CN114127084B (zh) 11-氧代-葫芦烷及其作为风味改良剂的用途
JPH01254696A (ja) 新規ステビオール配糖体および甘味剤
CN114901081A (zh) 丙二酰基甜菊醇糖苷及其可食用用途
CN120752224A (zh) 黄烷酮化合物及其作为风味修饰剂的用途
WO2021130046A1 (en) Triterpene glucuronides and their use as flavor modifiers

Legal Events

Date Code Title Description
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20190924